Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Retained Earnings (2016 - 2025)

ImmunityBio (IBRX) has disclosed Retained Earnings for 12 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 100.86% to $29.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.0 million, a 100.86% increase, with the full-year FY2025 number at $29.0 million, up 100.86% from a year prior.
  • Retained Earnings was $29.0 million for Q4 2025 at ImmunityBio, up from $5.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $29.0 million in Q4 2025 to a low of -$3.4 billion in Q4 2024.
  • A 5-year average of -$1.3 billion and a median of -$950.2 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 8075792.5% in 2024, then skyrocketed 285185.71% in 2025.
  • ImmunityBio's Retained Earnings stood at -$2.0 billion in 2021, then fell by 21.23% to -$2.4 billion in 2022, then dropped by 24.52% to -$3.0 billion in 2023, then decreased by 13.96% to -$3.4 billion in 2024, then soared by 100.86% to $29.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Retained Earnings are $29.0 million (Q4 2025), $5.0 million (Q3 2025), and $12.6 million (Q2 2025).